Nexsen Locks in FDA Pathway and Launches Multi-Region Rollout for GBS Diagnostic

Nexsen unveils multi-region commercialisation strategy for StrepSure diagnostic

Nexsen (ASX: NXN) has confirmed its FDA regulatory pathway and is now executing parallel market entry strategies across the United States, Asia-Pacific, and emerging markets for its StrepSure diagnostic. The Nexsen StrepSure Global Rollout represents a coordinated approach targeting initial commercialisation across multiple geographies simultaneously, rather than a single-market play.

The company is targeting FDA submission in Q4 2026 via the 510(k) pathway, following positive pre-submission engagement with the U.S. Food and Drug Administration. ISO 13485 certification is anticipated in early Q3 2026, with initial manufacturing capacity of approximately 1 million devices per annum established at the RMIT Sir Ian Potter Nanobiosensing Facility.

This announcement moves Nexsen from development-stage to active commercialisation execution, with defined regulatory milestones and early revenue pathways across multiple geographies running simultaneously. The parallel execution strategy provides visibility on near-term catalysts whilst positioning StrepSure for both rapid market entry in supportive jurisdictions and longer-term clearance in major markets.

Mark Muzzin, Managing Director

“Group B Streptococcus is one of the most consequential unmet clinical needs in maternal and neonatal health globally… With our FDA regulatory pathway now confirmed this month, we are excited to unveil our global roll-out strategy, which has been structured to accelerate clinical adoption in key markets and generate opportunities for early revenue as we advance towards our FDA clearance.”

U.S. regulatory pathway advances toward Q4 submission

The FDA has concurred with Nexsen’s clinical strategy incorporating both Australian and U.S. data, de-risking the clinical program and providing clear visibility on submission timing. The 510(k) pathway confirmation followed constructive pre-submission engagement on regulatory strategy, intended use, and analytical and clinical validation approach.

Clinical data collection is currently underway at Northern Health in Melbourne, Australia. In the recent Q-Sub meeting, the FDA confirmed agreement with Nexsen’s proposal to include data from Australia and two U.S. sites. Contracts for U.S. clinical site onboarding and contract research organisation (CRO) management are anticipated imminently.

Sequential steps toward FDA submission:

1. Complete clinical data collection at Northern Health (Melbourne)
2. Activate two U.S. clinical sites with CRO support
3. Finalise combined Australian and U.S. clinical dataset
4. Submit 510(k) application in Q4 2026

The FDA’s acceptance of a combined Australia-U.S. dataset reduces clinical trial complexity and accelerates the submission timeline compared to U.S.-only data requirements.

What is Group B Streptococcus and why rapid testing matters

Group B Streptococcus (GBS) is a bacterial infection affecting an estimated 18% of pregnant women globally. If undetected and untreated, GBS can lead to serious neonatal complications including sepsis, pneumonia, and meningitis. Current lab-based testing takes days to return results, making it unsuitable for use during labour when immediate treatment decisions are required.

StrepSure delivers results in approximately 20-30 minutes at point of care, enabling real-time clinical decision-making without laboratory equipment. The global addressable market represents approximately 132 million births annually, creating substantial commercial opportunity for rapid diagnostic solutions that address the timing gap in existing testing workflows.

The slow turnaround of existing tests creates a clear clinical need for rapid point-of-care diagnostics, positioning StrepSure as a solution to a recognised gap in maternal healthcare where timing is critical to neonatal outcomes.

Asia-Pacific and emerging markets offer early revenue pathways

Nexsen is executing parallel market entry strategies across Hong Kong, Malaysia, India, and Africa. These markets provide opportunities for clinical validation, early revenue generation, and real-world data collection ahead of U.S. regulatory clearance. The staged approach allows Nexsen to initiate commercial activities and scale distribution whilst progressing toward primary U.S. market entry.

Hong Kong positioned as initial commercial entry point

Hong Kong is being established as Nexsen’s initial commercial entry point, with local clinical validation underway through hospital partnerships. The territory serves as a gateway to China and broader North Asia markets, supporting subsequent regional expansion into high-population markets.

Nexsen has established Nexsen Hong Kong Limited as the planned long-term global manufacturing and distribution hub. Hong Kong’s status as a regional life sciences and health technology hub, combined with preferential pathways for Hong Kong-developed medical technologies into designated Mainland hospitals, positions the entity for scaled production and regional distribution.

Hong Kong’s free-port status supports global logistics, whilst existing relationships with clinicians across public hospitals, private providers, and associated research networks provide immediate pathways for piloting GBS testing in maternity, neonatal, renal, and critical care settings across the territory and the wider Greater Bay Area.

Hong Kong provides a supportive regulatory environment and immediate access to clinical demand, enabling early revenue generation whilst supporting regional expansion into China and North Asia.

Malaysia and India partnerships advancing

Nexsen is advancing distinct partnership strategies in Malaysia and India, each targeting local clinical validation, regulatory approvals, and manufacturing scale-up:

• Malaysia: A substantial partnership is emerging to support local clinical validation activities and expansion of Nexsen’s platform into additional disease indications. An identified contract manufacturer is already in place, providing a pathway toward manufacturing scale-up.

• India: The company is progressing engagement with a contract manufacturing organisation expected to support local regulatory approvals, large-scale manufacturing, and potential market access and distribution pathways.

These partnerships provide pathways to scale manufacturing capacity and establish distribution networks in high-population markets, reducing reliance on a single production facility whilst enabling market-specific regulatory compliance.

Emerging markets engagement with global health organisations

Following recent engagement in Africa, Nexsen has commenced discussions with non-government funding institutions (NFIs) and global health organisations to support clinical validation and deployment. The strategy centres on aligning with public health programs and institutional partners to enable adoption at scale.

High disease burden in emerging markets represents significant long-term opportunity, with institutional partnerships enabling adoption at scale through established healthcare frameworks.

Manufacturing and quality infrastructure progressing

Nexsen has established a clear manufacturing and quality pathway to support initial commercial supply and long-term global scale. Quality Management System (QMS) external audits are scheduled for Q2 2026, with ISO 13485 certification anticipated in early Q3 2026. Medical Device Single Audit Program (MDSAP) expansion is planned to follow, enabling regulatory compliance across multiple jurisdictions.

The RMIT Sir Ian Potter Nanobiosensing Facility will support initial production and early demand, with initial local manufacturing capacity of approximately 1 million devices per annum to enable commercial supply. In parallel, Nexsen Hong Kong Limited is being established as the planned global manufacturing hub for large-scale production, regional distribution, and global supply across all current and future diagnostic products.

Quality certification is a gating requirement for commercial sales across all jurisdictions. The parallel establishment of Hong Kong manufacturing positions Nexsen for long-term global scale beyond initial production capacity at the RMIT facility.

Near-term milestones and future outlook

Nexsen has outlined defined catalysts expected over the coming months as it progresses toward initial commercialisation:

1. Activation of U.S. clinical sites and progression of local trials
2. Continued clinical data generation in Australia
3. Advancement of Asia-Pacific clinical validation activities
4. Completion of QMS audits scheduled Q2 2026
5. Completion of ISO 13485 certification anticipated early Q3 2026
6. Ongoing development of early market entry initiatives across multiple regions

StrepSure represents the first commercial application of Nexsen’s diagnostic platform. Additional indications in development include renal diagnostics, bovine mastitis, and biosecurity applications. Each targets large, underserved markets reliant on slow or fragmented testing, providing multiple follow-on opportunities beyond the initial GBS indication.

The coming 6-12 months offer a steady pipeline of operational, regulatory, and commercial catalysts. Successful StrepSure rollout validates Nexsen’s ability to commercialise rapid point-of-care diagnostics at scale, with platform expansion providing multiple follow-on opportunities across human health, agriculture technology, and biosecurity applications.

StrepSure is currently an investigational device and has not yet received regulatory approval for clinical use in any jurisdiction.

Want the Next Healthcare Breakout in Your Inbox?

Join 20,000+ investors receiving FREE breaking ASX healthcare news within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to get market-moving announcements delivered straight to your inbox the moment they break.